Synopsis
Synopsis
0
USDMF
0
VMF
0
FDA Orange Book
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Bromide, Butylscopolammonium
2. Bromide, N-butylscopolammonium
3. Buscapine
4. Buscolysin
5. Buscopan
6. Butylscopolamine
7. Butylscopolammonium Bromide
8. Hyoscinbutylbromide
9. Hyoscine N Butylbromide
10. Hyoscine N-butylbromide
11. N Butylscopolammonium Bromide
12. N-butylbromide, Hyoscine
13. N-butylscopolammonium Bromide
14. Scopolaminebutylbromide
15. Scopolan
1. 149-64-4
2. N-butylscopolammonium Bromide
3. Hyoscine Butylbromide
4. Buscopan
5. Scopolan
6. Buscapine
7. Buscolysin
8. Scobutil
9. Sporamin
10. Amisepan
11. Buscapina
12. Butylmin
13. Donopon
14. Joscine
15. Monospan
16. Scobron
17. Scobutyl
18. Sparicon
19. Tirantil
20. Buscol
21. Scobro
22. Buscolamin
23. Butylscopolammonium Bromide
24. Butylscopolamine Bromide
25. Scopolamine Bromobutylate
26. Hyoscine-n-butyl Bromide
27. Buscolysine
28. Stilbron
29. Hyoscine Butyl Bromide
30. N-butylhyoscinium Bromide
31. Butylhyoscine
32. Scopolamine Butobromide
33. N-butylhyoscine Bromide
34. Scoburen
35. Stibron
36. Hyoscin-n-butyl Bromide
37. Scopolamine Butyl Bromide
38. Scopolamine N-butylbromide
39. N-butylscopolamine Bromide
40. Scopolamine N-butyl Bromide
41. N-butylscopolaminium Bromide
42. (-)-n-butylscopolamine Bromide
43. (-)-scopolamine Butylbromide
44. Mls000069755
45. 0gh9jx37c8
46. (-)-scopolamine N-butyl Bromide
47. Smr000058795
48. Dsstox_cid_2718
49. Dsstox_rid_76697
50. Dsstox_gsid_22718
51. Cas-149-64-4
52. Hyoscine Butobromide
53. Hyoscin-n-butylbromid
54. Butylscopolamin
55. Unii-0gh9jx37c8
56. Buskolamin
57. Antipan
58. Buscogast
59. Hyocimax
60. Scopinal
61. Spasmin
62. Hybrocare
63. Butylscopolamine Bromide [jan]
64. Sr-01000759230
65. Hyoscin-n-butylbromid [german]
66. Spasler-p
67. Hyoscin Butobromide
68. (1?,2?,4?,5?,7?)-9-butyl-7-[(2s)-3-hydroxy-1-oxo-2-phenylpropoxy]-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane Bromide
69. Einecs 205-744-1
70. Mfcd00078561
71. Opera_id_556
72. Ncgc00163224-01
73. Scopolamine (butylbromide)
74. Scopolamine N-n-butylbromide
75. Hyoscine-n-butyl Bromide Bp
76. Schembl25291
77. Mls002153372
78. Mls006013629
79. Chembl1256901
80. Dtxsid1022718
81. Chebi:32123
82. Hms2235k20
83. Hms3714i19
84. Hms3884j15
85. Hy-n0340
86. Tox21_112031
87. Hyoscine Butylbromide [mart.]
88. Scopolamine Butylbromide [jan]
89. Akos016009548
90. Akos037515799
91. Hyoscine Butylbromide [who-dd]
92. Tox21_112031_1
93. Ccg-208412
94. Cs-3142
95. Ncgc00186628-02
96. 3-oxa-9-azoniatricyclo(3.3.1.02,4)nonane, 9-butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, Bromide, (7(s)-(1alpha,2beta,4beta,5alpha,7beta))-
97. Ac-34139
98. As-78017
99. N-butylscopolammonium Bromide [mi]
100. Smr004705104
101. Hyoscine Butylbromide [ep Monograph]
102. Butylscopolamine Bromide [green Book]
103. F17660
104. A884250
105. J-008603
106. Sr-01000759230-3
107. N-butyl Scopolamine Bromide (n-butyl Hyoscine Bromide)
108. (-)-scopolamine N-butyl Bromide, >=98% (tlc), Powder
109. Hyoscine Butylbromide, British Pharmacopoeia (bp) Reference Standard
110. Hyoscine Butylbromide, European Pharmacopoeia (ep) Reference Standard
111. (1r,2r,4s,5s,7s)-9-butyl-7-{[(2s)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0~2,4~]nonane Bromide
112. (2r,4s,5s,7s)-9-butyl-7-{[(2s)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane Bromide
113. [(1s,2s,4r,5r)-9-butyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2s)-3-hydroxy-2-phenylpropanoate;bromide
114. 1-alpha-h,5-alpha-h-tropanium, 8-butyl-6-beta,7-beta-epoxy-3-alpha-hydroxy-, Bromide, (-)-tropate
115. 3-oxa-9-azoniatricyclo(3.3.1.0 Sup(2,4))nonane, 9-butyl-7-((2s)-3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, Bromide (1:1),(1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-
| Molecular Weight | 440.4 g/mol |
|---|---|
| Molecular Formula | C21H30BrNO4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 8 |
| Exact Mass | 439.13582 g/mol |
| Monoisotopic Mass | 439.13582 g/mol |
| Topological Polar Surface Area | 59.1 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 500 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Cara Care has teamed up with the Consumer Healthcare Business Unit of Sanofi Germany to provide Sanofi’s Buscomint® bei Reizdarm drug with Cara Care’s digital companion app for digestive conditions.
Lead Product(s): Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 22, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Sanofi
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Cara Care has teamed up with the Consumer Healthcare Business Unit of Sanofi Germany to provide Sanofi’s Buscomint® bei Reizdarm drug with Cara Care’s digital companion app for digestive conditions.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 22, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 05, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Determine the Bioequivalence of Two Formulations of Hyoscine Butylbromide.
Details : Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 05, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 10, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Voluntee...
Details : Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 10, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Abdominal Pain.
Lead Product(s): Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 17, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Abdominal Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 17, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colic.
Lead Product(s): Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 17, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 17, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Hyoscine N-Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gastrointestinal Diseases.
Lead Product(s): Hyoscine Butyl Bromide,Paracetamol
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 01, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hyoscine Butyl Bromide,Paracetamol
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Tolerability of Buscopan Plus in Painful Gastric or Intestinal Spasms
Details : Hyoscine N-Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gastrointestinal Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 01, 2014

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Buscopan (Hyoscine Butylbromide) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Intestinal Diseases.
Lead Product(s): Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Buscopan
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 27, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pa...
Details : Buscopan (Hyoscine Butylbromide) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Intestinal Diseases.
Product Name : Buscopan
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 27, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 28, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hyoscine Butyl Bromide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hyoscine Butylbromide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 28, 2012

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Withdrawn
Registration Country : Malta
Brand Name : Buscopan Ampoules
Dosage Form : Solution For Injection
Dosage Strength : 20MG/ML
Packaging :
Approval Date : 2017-08-01
Application Number :
Regulatory Info : Withdrawn
Registration Country : Malta
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Withdrawn
Registration Country : Malta
Brand Name : Buscopan Ibs Relief
Dosage Form : Tablet
Dosage Strength : 10MG
Packaging :
Approval Date : 2017-08-01
Application Number :
Regulatory Info : Withdrawn
Registration Country : Malta
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Withdrawn
Registration Country : Malta
Brand Name : Buscopan Ampoules
Dosage Form : Solution For Injection
Dosage Strength : 20MG/ML
Packaging :
Approval Date : 2018-12-03
Application Number :
Regulatory Info : Withdrawn
Registration Country : Malta
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Withdrawn
Registration Country : Malta
Brand Name : Buscopan Ampoules
Dosage Form : Solution For Injection
Dosage Strength : 20mg/ml
Packaging :
Approval Date : 2019-08-21
Application Number :
Regulatory Info : Withdrawn
Registration Country : Malta
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Cancelled
Registration Country : Spain
Metamizol Sodium; Butylscopolamine Bromide
Brand Name : Buscapina Compositum
Dosage Form : Coated Tablet
Dosage Strength : 250MG; 10 MG
Packaging :
Approval Date : 01-06-1959
Application Number : 32174
Regulatory Info : Cancelled
Registration Country : Spain
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : BUSCOPAN
Dosage Form : TABLET
Dosage Strength : 10MG
Packaging : 100
Approval Date :
Application Number : 363812
Regulatory Info : Ethical
Registration Country : Canada
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : BUSCOPAN
Dosage Form : SOLUTION
Dosage Strength : 20MG/ML
Packaging : 10X1ML
Approval Date :
Application Number : 363839
Regulatory Info : Prescription
Registration Country : Canada
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Australia
Brand Name : Buscopan
Dosage Form : injection
Dosage Strength : 20 mg/mL
Packaging : 5
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Australia
Brand Name : Buscopan
Dosage Form : injection
Dosage Strength : 20 mg/mL
Packaging : 5
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Australia
Brand Name : Buscopan
Dosage Form : injection
Dosage Strength : 20 mg/mL
Packaging : 5
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
48
PharmaCompass offers a list of Hyoscine Butyl Bromide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Hyoscine Butyl Bromide manufacturer or Hyoscine Butyl Bromide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Hyoscine Butyl Bromide manufacturer or Hyoscine Butyl Bromide supplier.
PharmaCompass also assists you with knowing the Hyoscine Butyl Bromide API Price utilized in the formulation of products. Hyoscine Butyl Bromide API Price is not always fixed or binding as the Hyoscine Butyl Bromide Price is obtained through a variety of data sources. The Hyoscine Butyl Bromide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Hyoscinbutylbromide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Hyoscinbutylbromide, including repackagers and relabelers. The FDA regulates Hyoscinbutylbromide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Hyoscinbutylbromide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Hyoscinbutylbromide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Hyoscinbutylbromide supplier is an individual or a company that provides Hyoscinbutylbromide active pharmaceutical ingredient (API) or Hyoscinbutylbromide finished formulations upon request. The Hyoscinbutylbromide suppliers may include Hyoscinbutylbromide API manufacturers, exporters, distributors and traders.
click here to find a list of Hyoscinbutylbromide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Hyoscinbutylbromide Drug Master File in Japan (Hyoscinbutylbromide JDMF) empowers Hyoscinbutylbromide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Hyoscinbutylbromide JDMF during the approval evaluation for pharmaceutical products. At the time of Hyoscinbutylbromide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Hyoscinbutylbromide suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Hyoscinbutylbromide Drug Master File in Korea (Hyoscinbutylbromide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Hyoscinbutylbromide. The MFDS reviews the Hyoscinbutylbromide KDMF as part of the drug registration process and uses the information provided in the Hyoscinbutylbromide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Hyoscinbutylbromide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Hyoscinbutylbromide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Hyoscinbutylbromide suppliers with KDMF on PharmaCompass.
A Hyoscinbutylbromide CEP of the European Pharmacopoeia monograph is often referred to as a Hyoscinbutylbromide Certificate of Suitability (COS). The purpose of a Hyoscinbutylbromide CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Hyoscinbutylbromide EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Hyoscinbutylbromide to their clients by showing that a Hyoscinbutylbromide CEP has been issued for it. The manufacturer submits a Hyoscinbutylbromide CEP (COS) as part of the market authorization procedure, and it takes on the role of a Hyoscinbutylbromide CEP holder for the record. Additionally, the data presented in the Hyoscinbutylbromide CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Hyoscinbutylbromide DMF.
A Hyoscinbutylbromide CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Hyoscinbutylbromide CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Hyoscinbutylbromide suppliers with CEP (COS) on PharmaCompass.
A Hyoscinbutylbromide written confirmation (Hyoscinbutylbromide WC) is an official document issued by a regulatory agency to a Hyoscinbutylbromide manufacturer, verifying that the manufacturing facility of a Hyoscinbutylbromide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Hyoscinbutylbromide APIs or Hyoscinbutylbromide finished pharmaceutical products to another nation, regulatory agencies frequently require a Hyoscinbutylbromide WC (written confirmation) as part of the regulatory process.
click here to find a list of Hyoscinbutylbromide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Hyoscinbutylbromide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Hyoscinbutylbromide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Hyoscinbutylbromide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Hyoscinbutylbromide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Hyoscinbutylbromide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Hyoscinbutylbromide suppliers with NDC on PharmaCompass.
Hyoscinbutylbromide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Hyoscinbutylbromide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Hyoscinbutylbromide GMP manufacturer or Hyoscinbutylbromide GMP API supplier for your needs.
A Hyoscinbutylbromide CoA (Certificate of Analysis) is a formal document that attests to Hyoscinbutylbromide's compliance with Hyoscinbutylbromide specifications and serves as a tool for batch-level quality control.
Hyoscinbutylbromide CoA mostly includes findings from lab analyses of a specific batch. For each Hyoscinbutylbromide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Hyoscinbutylbromide may be tested according to a variety of international standards, such as European Pharmacopoeia (Hyoscinbutylbromide EP), Hyoscinbutylbromide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Hyoscinbutylbromide USP).